Alivus Life Sciences Ltd

Alivus Life Sciences Q3 FY26: Strong Revenue & Margin Growth 📈

- Q3 FY26 revenue: ₹6,729M (14.4% QoQ, 4.8% YoY growth)

- EBITDA: ₹2,452M (26.5% QoQ, 22.1% YoY growth)

- PAT: ₹1,503M (15.5% QoQ, 9.7% YoY growth)

- Gross margins improved to 58.9% (+120 bps QoQ, +330 bps YoY)

- EBITDA margins rose to 36.4% (+340 bps QoQ, +510 bps YoY)

- CDMO segment revenue grew 100% QoQ and 85.3% YoY

- Non-GPL revenues for 9MFY26: ₹13,646M (+16.1% YoY)

- Regulated markets contributed 83% of Q3 revenue; chronic therapies accounted for 66%

- Free cash flow: ₹2,207M in 9MFY26; cash & equivalents: ₹7,330M as of Dec 31, 2025

- ROICE: ~31%; FATR: 2.3x

- Cumulative DMF/CEP filings: 595 as of Dec 31, 2025

- Capacity expansion plans: Brownfield additions in Ankleshwar & Dahej; greenfield expansion in Solapur

- Future growth strategies: CDMO ramp-up, complex API platforms, operational efficiencies